{"organizations": [], "uuid": "94d37a6df7a60e911bd76528ff711c6a4fdf76c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-weill-cor/brief-nanobiotix-partners-with-weill-cornell-medicine-idUSFWN1SA1BN", "country": "US", "domain_rank": 408, "title": "Nanobiotix Partners With Weill Cornell Medicine", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.971, "site_type": "news", "published": "2018-05-04T01:42:00.000+03:00", "replies_count": 0, "uuid": "94d37a6df7a60e911bd76528ff711c6a4fdf76c3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-weill-cor/brief-nanobiotix-partners-with-weill-cornell-medicine-idUSFWN1SA1BN", "ord_in_thread": 0, "title": "Nanobiotix Partners With Weill Cornell Medicine", "locations": [], "entities": {"persons": [{"name": "nanobiotix", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "cornell", "sentiment": "negative"}, {"name": "nanobiotix partners with weill cornell medicine may", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - NANOBIOTIX SA:\n* PARTNERS WITH WEILL CORNELL MEDICINE * PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS\n* TRIAL THAT SHALL START IN Q2 2018, AIMS TO EXPAND POTENTIAL OF NBTXR3\n* COLLABORATION WILL BE CONDUCTED OVER COURSE OF 1 YEAR, WITH GOAL OF CONTINUING EXPLORATION OF ROLE OF NBTXR3 IN IMMUNO-ONCOLOGY Source text for Eikon: (Gdynia Newsroom)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T01:42:00.000+03:00", "crawled": "2018-05-04T16:46:15.000+03:00", "highlightTitle": ""}